Literature DB >> 27373814

Glycolysis inhibition as a cancer treatment and its role in an anti-tumour immune response.

Kheshwant S Gill1, Philana Fernandes2, Tracey R O'Donovan2, Sharon L McKenna2, Kishore K Doddakula3, Derek G Power4, Declan M Soden2, Patrick F Forde5.   

Abstract

Increased glycolysis is the main source of energy supply in cancer cells that use this metabolic pathway for ATP generation. Altered energy metabolism is a biochemical fingerprint of cancer cells that represents one of the "hallmarks of cancer". The immune system can prevent tumour growth by eliminating cancer cells but this editing process ultimately results in poorly immunogenic cells remaining allowing for unchallenged tumour growth. In this review we look at the glycolysis pathway as a target for cancer treatments. We also examine the interplay between the glycolysis modulation and the immune response as an anti-cancer therapy.
Copyright © 2016. Published by Elsevier B.V.

Entities:  

Keywords:  Electroporation; Glycolysis; Glycolytic modulator; Immune-metabolic interaction

Mesh:

Substances:

Year:  2016        PMID: 27373814     DOI: 10.1016/j.bbcan.2016.06.005

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  47 in total

1.  Kinetic analysis, size profiling, and bioenergetic association of DNA released by selected cell lines in vitro.

Authors:  Janine Aucamp; Abel J Bronkhorst; Dimetrie L Peters; Hayley C Van Dyk; Francois H Van der Westhuizen; Piet J Pretorius
Journal:  Cell Mol Life Sci       Date:  2017-03-18       Impact factor: 9.261

Review 2.  The promise and peril of targeting cell metabolism for cancer therapy.

Authors:  Jonathan M Weiss
Journal:  Cancer Immunol Immunother       Date:  2019-11-28       Impact factor: 6.968

3.  Low expression of miR-195 is associated with cell proliferation, glycolysis and poor survival in estrogen receptor (ER)-positive but not in triple negative breast cancer.

Authors:  Yoshihisa Tokumaru; Masanori Oshi; Ankit Patel; Eriko Katsuta; Li Yan; Fernando A Angarita; Subhamoy Dasgupta; Masayuki Nagahashi; Nobuhisa Matsuhashi; Manabu Futamura; Kazuhiro Yoshida; Kazuaki Takabe
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

4.  Reciprocal REGγ-mTORC1 regulation promotes glycolytic metabolism in hepatocellular carcinoma.

Authors:  Liangfang Yao; Yang Xuan; Haiyang Zhang; Bo Yang; Xinglong Ma; Tianzhen Wang; Tianyuan Meng; Wenshe Sun; Haibin Wei; Xueqing Ma; Robb Moses; Jianru Xiao; Pei Zhang; Chao Ge; Jinjun Li; Lei Li; Xiaotao Li; Jinbao Li; Bianhong Zhang
Journal:  Oncogene       Date:  2020-11-23       Impact factor: 9.867

5.  TSP50 promotes the Warburg effect and hepatocyte proliferation via regulating PKM2 acetylation.

Authors:  Feng Gao; Xiaojun Zhang; Shuyue Wang; Lihua Zheng; Ying Sun; Guannan Wang; Zhenbo Song; Yongli Bao
Journal:  Cell Death Dis       Date:  2021-05-20       Impact factor: 8.469

6.  Phenotypic Plasticity Conferred by the Metastatic Microenvironment of the Brain Strengthens the Intracranial Tumorigenicity of Lung Tumor Cells.

Authors:  Xu-Ge Wei; Ke-Wei Bi; Bo Li
Journal:  Front Oncol       Date:  2021-05-13       Impact factor: 6.244

7.  Inhibiting Glucose Metabolism By miR-34a and miR-125b Protects Against Hyperglycemia-Induced Cardiomyocyte Cell Death.

Authors:  Chao-Rui Xu; Qiu-Ju Fang
Journal:  Arq Bras Cardiol       Date:  2021-03       Impact factor: 2.000

8.  WW domain-binding protein 2 acts as an oncogene by modulating the activity of the glycolytic enzyme ENO1 in glioma.

Authors:  Shuai Chen; Ya Zhang; Han Wang; Yu-Ying Zeng; Zhi Li; Ming-Li Li; Fang-Fang Li; Jun You; Zhi-Ming Zhang; Chi-Meng Tzeng
Journal:  Cell Death Dis       Date:  2018-03-01       Impact factor: 8.469

9.  Low-Dose Paclitaxel Inhibits Tumor Cell Growth by Regulating Glutaminolysis in Colorectal Carcinoma Cells.

Authors:  Chaoxiang Lv; Hao Qu; Wanyun Zhu; Kaixiang Xu; Anyong Xu; Baoyu Jia; Yubo Qing; Honghui Li; Hong-Jiang Wei; Hong-Ye Zhao
Journal:  Front Pharmacol       Date:  2017-05-04       Impact factor: 5.810

10.  BCKDK of BCAA Catabolism Cross-talking With the MAPK Pathway Promotes Tumorigenesis of Colorectal Cancer.

Authors:  Peipei Xue; Fanfan Zeng; Qiuhong Duan; Juanjuan Xiao; Lin Liu; Ping Yuan; Linni Fan; Huimin Sun; Olesya S Malyarenko; Hui Lu; Ruijuan Xiu; Shaoqing Liu; Chen Shao; Jianmin Zhang; Wei Yan; Zhe Wang; Jianyong Zheng; Feng Zhu
Journal:  EBioMedicine       Date:  2017-05-04       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.